Two more Peninsula IPOs tell the story of biotech's investment boom

Two Bay Area biotech companies — one that started its first clinical trial in eye diseases in July, the other a pioneer in the fledgling field of hunting down cancer via a simple blood draw — seek to raise $100 million each in the region’s 14th and 15th life sciences initial public offerings this year.